News_CSPC

: 2026/ 05/11

2026 AACR: SYS6010 Nasopharyngeal Carcinoma Research Results Released by CSPC Innovation

From April 17 to 22, the 117th Annual Meeting of the American Association for Cancer Research (AACR) was held in San Diego, USA.

: 2026/ 04/28

Five innovative drug research achievements of CSPC Innovation have been selected for the

From May 29 to June 2, 2026, the annual meeting of the American Society of Clinical Oncology (ASCO) will be held in Chicago, USA. At this year’s ASCO conference, CSPC Innovation will present five latest clinical trial progressions of four pipeline products.

: 2025/ 11/18

CSPC Innovative Presents Omalizumab for Injection at 2025 National Congress of Aesthetic Dermatology

From November 6 to 9, the "20th Annual Meeting of the Dermatologists Branch of the Chinese Medical Doctor Association & National Congress of Aesthetic Dermatology" (CDA for short), hosted by the Chinese Medical Doctor Association and the Dermatologists Branch of the Chinese Medical Doctor Association, was grandly held at the Chongqing Science Hall. A large number of experts and scholars in the field of dermatology from across the country gathered at the event.

: 2025/ 11/11

CSPC Innovation Successfully Passes BRCGS Certification

Recently, CSPC Pharmaceutical Innovation Pharmaceutical Co., Ltd. (hereinafter referred to as “CSPC Pharmaceutical Innovation”) has successfully passed the on-site audit of the BRCGS Food Safety System and obtained an A-grade rating.

: 2025/ 09/26

CSPC Innovation Guoweikang Supports the 2025 Hengshui Lake Marathon, Safeguarding Runners' Journey with "Healthy Refueling"

On September 21, the 2025 Hengshui Lake Marathon & National Marathon Championships (Station 2) kicked off spectacularly amid crisp autumn weather. Twenty thousand runners gathered in Hengshui, breezing through the race with the fresh lakeside wind, and experiencing the city's vitality and ecological charm through running.

: 2025/ 08/16

CSPC Innovation Releases 2025 Interim Report, with R&D Expenses Increasing 81% Year-on-Year

Following their approval for marketing in 2024, Enlangsubai Monoclonal Antibody Injection (recombinant anti-PD-1 fully human monoclonal antibody) and Omalizumab for Injection (recombinant anti-IgE humanized monoclonal antibody) have been rolled out in an orderly manner and quickly entered commercial sales, becoming new growth drivers for the company’s biopharmaceutical revenue in 2025.

: 2025/ 08/03

CSPC Innovation Successfully Hosted the Urticaria Session at the 2025 Annual Meeting of the Professional Committee of Dermatological Pharmacy

From July 25 to 27, 2025 Annual Meeting of the Dermatological Pharmacy Committee was grandly held in Shijiazhuang, co-hosted by the Dermatological Pharmacy Professional Committee of Hebei Pharmaceutical Association and the First Hospital of Hebei Medical University. During the conference, CSPC Innovation co-organized the Urticaria Session, where renowned dermatology experts from across China gathered for academic exchanges on advances in the diagnosis and treatment of urticaria, interpretation of the latest guidelines, and the therapeutic advantages of CSPC Omalizumab.

: 2025/ 07/08

Authoritative Urticaria Guideline Tour Focuses on CSPC Innovation's Omalizumab

Recently, the "Journey of Urticaria · Face-to-Face with Experts" tour conference on urticaria diagnosis and treatment guidelines was held in Yanji. Renowned authoritative experts in dermatology from across the country gathered to exchange views on cutting-edge advances in dermatology, relevant policies and regulations, and the latest guidelines in the field of urticaria.

: 2025/ 06/04

CSPC Zhongnuo Taizhou Company Awarded "Jiangsu Provincial Advanced Smart Factory"

Recently, the Department of Industry and Information Technology of Jiangsu Province issued the Announcement on the List of 2025 Jiangsu Provincial Advanced Smart Factories.The "Smart Factory for Health Foods Based on Full‑Process Data Collaboration" submitted by CSPC Zhongnuo Pharmaceutical (Taizhou) Co., Ltd. (hereinafter referred to as "CSPC Zhongnuo Taizhou"), a subsidiary of CSPC Innovation, has successfully passed the evaluation with its outstanding performance in intelligent manufacturing, becoming an excellent model in the field of intelligent manufacturing in Jiangsu Province.

: 2025/ 05/20

CSPC Innovation’s SYS6010 (CPO301) Antibody-Drug Conjugate Granted Fast Track Designation by the U.S. FDA

On May 19, CSPC Innovation Pharmaceutical Co., Ltd. announced that SYS6010 (CPO301), developed by JW Therapeutics Co., Ltd., a subsidiary held by the Company, has recently been granted **Fast Track Designation (FTD)** by the U.S. Food and Drug Administration (FDA).

The indication is for the treatment of adult patients with advanced or metastatic non-squamous non-small cell lung cancer (Nsq-NSCLC) **without epidermal growth factor receptor (EGFR) mutations or other driver gene alterations (AGA)**, whose disease has progressed following prior platinum-containing chemotherapy and anti-PD-(L)1 therapy.

COMPANY NEWS